Overview

Corporate Presentation

Corporate Presentation - November 2022

Download Presentation

Email Alerts

Register to receive real time alerts

Sign Up

IR Contacts

Get in touch with our IR team

Contact Us

Latest Press Releases
Nov 14, 2022

David Clark, MD, MRCP, will lead the continued development of Haduvio™ NEW HAVEN, Conn., Nov. 14, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical...

Nov 10, 2022

Management to host a conference call and webcast today at 4:30 p.m. EDT NEW HAVEN, Conn., Nov. 10, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical...

Nov 8, 2022

Fireside chat will be held on Wednesday, November 16, 2022, from 3:35 p.m. to 4:05 p.m. EDT NEW HAVEN, Conn., Nov. 8, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage...

View All Press Releases

Events
Wednesday, November 16, 2022
3:35pm - 4:05pm EST

View All Events

We are developing the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems.

Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options.

Explore Our Pipeline